MDLinx E-mail Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 emails at a time.

* From Email: 
* To Email: 
To Email: 
To Email: 
To Email: 
To Email: 
Email Subject Line: 

Sustained safety and efficacy of once-daily hydromorphone extended-release (oros hydromorphone er) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain

Richarz U et al. – The majority of patients receiving OROS hydromorphone ER (88.3%) and oxycodone CR (88.5%) rated tolerability as good or very good at Week 52; few patients discontinued treatment because of an adverse event (1.6% vs. 0.4%, respectively). The effectiveness of OROS hydromorphone ER and oxycodone CR was maintained through 1 year.

  • An open–label, randomized, 24–week, parallel group, flexible–dose study demonstrated noninferiority of OROS hydromorphone ER vs. twice–daily oxycodone CR in patients with chronic noncancer pain.
  • In total, 112 patients were enrolled in a 28–week, open–label extension study; 60 patients received OROS hydromorphone ER and 52 received oxycodone CR.
  • The primary efficacy measure was the change from baseline to Weeks 38 and 52 in Brief Pain Inventory item “pain right now.”
  • Global assessments of efficacy, dosing convenience, and tolerability were secondary endpoints.
  • Mean change in “pain right now” from baseline to Week 38 was –3.0 (OROS hydromorphone ER) vs. –2.8 (oxycodone CR), and from baseline to Week 52 was –2.9 vs. –2.8; these changes were similar to the changes in the core phase (–2.1 vs. –2.1).

  • Similar improvements were demonstrated for secondary assessments, including pain, pain interference, and quality of life.
  • At Week 52, global assessment of efficacy was rated as “very good” or “good” by the majority of patients (OROS hydromorphone ER, 91.7%; oxycodone CR, 86.5%).
  • More patients in the OROS hydromorphone ER group (35.0% vs. 21.2%) assessed mode of drug intake as “very convenient.”

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More